Is enclomiphene really superior to clomid?

Theoretically yes, in practice nuanced. Pharmacological logic supports that the trans isomer (enclomiphene) is the 'pure' hypothalamic anti-estrogen active element, and that the cis isomer (zuclomiphene) of the clomid mixture contributes to side effects (residual estrogenic, long-term accumulation with 5-7 day half-life). But pivot RCTs on human PCT (Katz 2012, Whitten 2006) use the clomid mixture with demonstrated efficacy. The clinical superiority of pure enclomiphene remains to be confirmed by direct comparative trials.

What enclomiphene dose?

Equivalent in activity to clomid at 50% of the dose (since clomid contains ~50-60% enclomiphene). Typical dose in PCT: 12.5 mg/d to 25 mg/d × 4 weeks. The Androxal program (Repros) tested 12.5-25 mg/d doses in hypogonadic men with effects on testo equivalent to clomid at 25-50 mg/d. Start at 12.5 mg/d × 1 week to assess individual tolerance, then adjust.

Is zuclomiphene responsible for visual disturbances?

Plausible hypothesis but not formally demonstrated. Purvin 1995 documented ocular toxicity under clomiphene citrate (mixture) without distinguishing the contribution of the two isomers. Zuclomiphene, with its long half-life and partial estrogen agonist activity, is a candidate for explaining some neuropsychiatric and ocular effects. Pure enclomiphene, by deduction, should have a more tolerable profile — confirmed by limited Androxal trials but without direct comparative study in bodybuilder PCT.

Enclomiphene availability?

Limited. No FDA approval (the Androxal program failed in phase 3 on secondary hypogonadism for methodological reasons). A few compounding pharmacies in the United States and some TRT clinics offer pure enclomiphene by prescription. The underground market offers powders and capsules, very variable quality. Independent lab tests recommended before cycle.

Enclomiphene as alternative TRT?

Emerging approach. Several American TRT clinics offer enclomiphene 12.5-25 mg/d as alternative to exogenous testosterone in secondary hypogonadic men (intact HPG axis but underfunctioning). Advantages: fertility maintained (enclomiphene stimulates endogenous LH/FSH), no injection, no erythrocytosis risk. Drawbacks: partial effect (T total raises to 500-700 ng/dL vs 800-1000 under testo TRT), not officially approved, limited long-term data. For users wanting to preserve fertility, interesting option under clinical follow-up.

How long to take enclomiphene in PCT?

4 weeks standard, extendable to 6-8 weeks if unsatisfactory T total panel at W4 post-PCT. Short half-life (~10 h) allows rapid stop at end of protocol without prolonged accumulation (unlike clomid mixture which can remain active via zuclomiphene for 2-3 weeks after last intake). T total, LH, FSH panel at W4 and W8 post-PCT to confirm recovery.

What side effects under pure enclomiphene?

Theoretically rarer than with clomid mixture. The Androxal program (Repros Therapeutics, never FDA approved) reported a tolerable profile with occasional headaches, hot flashes, and mild nausea. No concerning signal on visual disturbances (attributed to zuclomiphene in clomid). No marked mood effect. Practical profile in bodybuilder PCT limited by lack of direct comparative data. Standard clinical monitoring remains essential.

Enclomiphene to boost testosterone naturally?

This is the use promoted by some alternative TRT clinics. In secondary hypogonadic man (functional but underactive HPG axis), enclomiphene 12.5-25 mg/d can elevate T total by 200-300 ng/dL in a few weeks. Testicle maintenance, fertility preserved, no injection. Drawbacks: plateau effect reached at 6-8 weeks, T total rarely > 800 ng/dL even at high dose. For primary hypogonadism (dysfunctional testicles), ineffective. Primary vs secondary hypogonadism differential diagnosis essential.

Enclomiphene vs Clomid: complete comparison (pure isomer vs mixture)

Critère	enclomiphene	clomid
Composition	Pure trans-clomiphene (1 isomer)	Trans+cis mixture (~60/40)
Residual estrogenic activity	None (pure anti-estro)	Present (zuclomiphene)
Half-life	~10 h	~5-7 d (long zuclomiphene)
Estrogenic side effects	Rarer	More frequent (mood, visual)
FDA approval	No (never validated)	Yes (formerly fertility)
Cost	Expensive (UGL)	Accessible (generic)
PCT studies	Limited	Multiple (Katz, Whitten, etc.)
WADA status	Banned (PCT)	Banned (PCT)

Quand choisir enclomiphene

Pure enclomiphene is the trans isomer of clomiphene citrate (~60% of the total clomid mixture). Its theoretical interest: act as pure hypothalamic anti-estrogen without the partial estrogen agonist counter-effect of zuclomiphene (cis isomer, 40% of clomid mixture). Choose it for: (1) a PCT with fewer estrogenic side effects (mood swings, visual disturbances sometimes attributed to zuclomiphene), (2) a user having poorly tolerated standard clomid (marked neuropsychiatric effects), (3) a 'purer' PCT on the hypothalamic anti-estrogen mechanism without residual isomer, (4) a cycle to restart endogenous testosterone in secondary hypogonadic user as alternative to classic TRT. Pharmacological profile: pure hypothalamic estrogen antagonist, short half-life (~10 h) without zuclomiphene accumulation unlike clomid mixture, expected endogenous LH/FSH elevation similar to clomid at equivalent dose. The Androxal development program (Repros Therapeutics) aimed at having it approved for male secondary hypogonadism — never resulted in FDA approval after two phase 3 failures for methodological reasons. Practical drawbacks: limited availability (essentially underground, few pharmacies offer it), higher cost than generic clomid, limited comparative study corpus in bodybuilder user. Typical dose in PCT: 12.5-25 mg/d × 4 weeks (equivalent in activity to clomid 25-50 mg/d).

Quand choisir clomid

Clomid (clomiphene citrate, enclomiphene + zuclomiphene mixture) is the historical reference SERM for PCT. Katz 2012 (RCT, +146% LH and +97% T at 25 mg/d), Whitten 2006 and Guay 2003 document its efficacy in hypogonadic men with parameter restoration at 3-6 months. Choose it for: (1) standard accessible PCT at reasonable cost and widely available, (2) a long cycle or with strong-suppression compounds where the robustness of restart matters more than profile nuances, (3) a user already familiar with clomid having no notable side effects in previous cycles. Pharmacological profile: mixture of isomers (~60% trans-enclomiphene, ~40% cis-zuclomiphene), total half-life ~5-7 days due to long-half-life zuclomiphene that accumulates progressively over intakes. Mechanism: antagonism of hypothalamic estrogen receptor → lifting negative feedback → increased GnRH pulses → LH/FSH restart → restoration of testicular steroidogenesis. Drawbacks to anticipate (Purvin 1995, Rahnema 2014): possible visual disturbances (1-5% of users, poorly understood ocular mechanism), mood swings, irritability, increased emotional sensitivity — often attributable to zuclomiphene. Typical dose 50/25/25/25 mg over 4 weeks in PCT. Wide accessibility and low cost (generic available).

Combinaison ?

Combining enclomiphene + clomid has no pharmacological sense: pure enclomiphene is already the main active component of clomid mixture. The coherent practice is to choose one OR the other, not both. If the goal is effective PCT with clean profile (few neuropsychiatric side effects): pure enclomiphene 12.5-25 mg/d × 4 weeks (if available and authentic). If accessibility and practical standard: clomid 50/25/25/25 mg over 4 weeks. In both cases, add nolvadex 20-40 mg/d × 4 weeks for anti-gyno protection and complementary restart effect, and hCG 1500 IU EOD × 10 days as pre-SERM bridge if long cycle with testicular atrophy. Biological monitoring: T total, LH, FSH, E2 at W0 (before PCT) then W4 and W8 post-PCT to confirm recovery. If unsatisfactory panel at W4 (T total < 300 ng/dL), extend 2-4 weeks with the chosen SERM. Complete panel and signs of HPG axis recovery are the only true criteria of PCT success. Sample PCT timeline after long cycle, choosing enclomiphene pure: W0 last long-ester injection, W2-W3 hCG 1500 IU EOD × 5 doses (10 days), W4 enclomiphene 12.5-25 mg/d start, W4 + nolvadex 20 mg/d (combo for anti-gyno coverage), W8 SERM end, W12 post-PCT panel (T total, LH, FSH, E2), W16 follow-up. Sample TRT-alternative use in secondary hypogonadism: enclomiphene 12.5 mg/d continuous, monthly T total/E2/LH check for first 3 months, then quarterly. Plateau typically at month 2-3. Independent lab testing for enclomiphene authenticity: underground market quality variable — prefer compounding pharmacy sources if possible.

FAQ

Is enclomiphene really superior to clomid?: Theoretically yes, in practice nuanced. Pharmacological logic supports that the trans isomer (enclomiphene) is the 'pure' hypothalamic anti-estrogen active element, and that the cis isomer (zuclomiphene) of the clomid mixture contributes to side effects (residual estrogenic, long-term accumulation with 5-7 day half-life). But pivot RCTs on human PCT (Katz 2012, Whitten 2006) use the clomid mixture with demonstrated efficacy. The clinical superiority of pure enclomiphene remains to be confirmed by direct comparative trials.
What enclomiphene dose?: Equivalent in activity to clomid at 50% of the dose (since clomid contains ~50-60% enclomiphene). Typical dose in PCT: 12.5 mg/d to 25 mg/d × 4 weeks. The Androxal program (Repros) tested 12.5-25 mg/d doses in hypogonadic men with effects on testo equivalent to clomid at 25-50 mg/d. Start at 12.5 mg/d × 1 week to assess individual tolerance, then adjust.
Is zuclomiphene responsible for visual disturbances?: Plausible hypothesis but not formally demonstrated. Purvin 1995 documented ocular toxicity under clomiphene citrate (mixture) without distinguishing the contribution of the two isomers. Zuclomiphene, with its long half-life and partial estrogen agonist activity, is a candidate for explaining some neuropsychiatric and ocular effects. Pure enclomiphene, by deduction, should have a more tolerable profile — confirmed by limited Androxal trials but without direct comparative study in bodybuilder PCT.
Enclomiphene availability?: Limited. No FDA approval (the Androxal program failed in phase 3 on secondary hypogonadism for methodological reasons). A few compounding pharmacies in the United States and some TRT clinics offer pure enclomiphene by prescription. The underground market offers powders and capsules, very variable quality. Independent lab tests recommended before cycle.
Enclomiphene as alternative TRT?: Emerging approach. Several American TRT clinics offer enclomiphene 12.5-25 mg/d as alternative to exogenous testosterone in secondary hypogonadic men (intact HPG axis but underfunctioning). Advantages: fertility maintained (enclomiphene stimulates endogenous LH/FSH), no injection, no erythrocytosis risk. Drawbacks: partial effect (T total raises to 500-700 ng/dL vs 800-1000 under testo TRT), not officially approved, limited long-term data. For users wanting to preserve fertility, interesting option under clinical follow-up.
How long to take enclomiphene in PCT?: 4 weeks standard, extendable to 6-8 weeks if unsatisfactory T total panel at W4 post-PCT. Short half-life (~10 h) allows rapid stop at end of protocol without prolonged accumulation (unlike clomid mixture which can remain active via zuclomiphene for 2-3 weeks after last intake). T total, LH, FSH panel at W4 and W8 post-PCT to confirm recovery.
What side effects under pure enclomiphene?: Theoretically rarer than with clomid mixture. The Androxal program (Repros Therapeutics, never FDA approved) reported a tolerable profile with occasional headaches, hot flashes, and mild nausea. No concerning signal on visual disturbances (attributed to zuclomiphene in clomid). No marked mood effect. Practical profile in bodybuilder PCT limited by lack of direct comparative data. Standard clinical monitoring remains essential.
Enclomiphene to boost testosterone naturally?: This is the use promoted by some alternative TRT clinics. In secondary hypogonadic man (functional but underactive HPG axis), enclomiphene 12.5-25 mg/d can elevate T total by 200-300 ng/dL in a few weeks. Testicle maintenance, fertility preserved, no injection. Drawbacks: plateau effect reached at 6-8 weeks, T total rarely > 800 ng/dL even at high dose. For primary hypogonadism (dysfunctional testicles), ineffective. Primary vs secondary hypogonadism differential diagnosis essential.

Enclomiphene vs Clomid: complete comparison (pure isomer vs mixture)

Critère	enclomiphene	clomid
Composition	Pure trans-clomiphene (1 isomer)	Trans+cis mixture (~60/40)
Residual estrogenic activity	None (pure anti-estro)	Present (zuclomiphene)
Half-life	~10 h	~5-7 d (long zuclomiphene)
Estrogenic side effects	Rarer	More frequent (mood, visual)
FDA approval	No (never validated)	Yes (formerly fertility)
Cost	Expensive (UGL)	Accessible (generic)
PCT studies	Limited	Multiple (Katz, Whitten, etc.)
WADA status	Banned (PCT)	Banned (PCT)

Quand choisir enclomiphene

Quand choisir clomid

Combinaison ?

FAQ

Is enclomiphene really superior to clomid?: Theoretically yes, in practice nuanced. Pharmacological logic supports that the trans isomer (enclomiphene) is the 'pure' hypothalamic anti-estrogen active element, and that the cis isomer (zuclomiphene) of the clomid mixture contributes to side effects (residual estrogenic, long-term accumulation with 5-7 day half-life). But pivot RCTs on human PCT (Katz 2012, Whitten 2006) use the clomid mixture with demonstrated efficacy. The clinical superiority of pure enclomiphene remains to be confirmed by direct comparative trials.
What enclomiphene dose?: Equivalent in activity to clomid at 50% of the dose (since clomid contains ~50-60% enclomiphene). Typical dose in PCT: 12.5 mg/d to 25 mg/d × 4 weeks. The Androxal program (Repros) tested 12.5-25 mg/d doses in hypogonadic men with effects on testo equivalent to clomid at 25-50 mg/d. Start at 12.5 mg/d × 1 week to assess individual tolerance, then adjust.
Is zuclomiphene responsible for visual disturbances?: Plausible hypothesis but not formally demonstrated. Purvin 1995 documented ocular toxicity under clomiphene citrate (mixture) without distinguishing the contribution of the two isomers. Zuclomiphene, with its long half-life and partial estrogen agonist activity, is a candidate for explaining some neuropsychiatric and ocular effects. Pure enclomiphene, by deduction, should have a more tolerable profile — confirmed by limited Androxal trials but without direct comparative study in bodybuilder PCT.
Enclomiphene availability?: Limited. No FDA approval (the Androxal program failed in phase 3 on secondary hypogonadism for methodological reasons). A few compounding pharmacies in the United States and some TRT clinics offer pure enclomiphene by prescription. The underground market offers powders and capsules, very variable quality. Independent lab tests recommended before cycle.
Enclomiphene as alternative TRT?: Emerging approach. Several American TRT clinics offer enclomiphene 12.5-25 mg/d as alternative to exogenous testosterone in secondary hypogonadic men (intact HPG axis but underfunctioning). Advantages: fertility maintained (enclomiphene stimulates endogenous LH/FSH), no injection, no erythrocytosis risk. Drawbacks: partial effect (T total raises to 500-700 ng/dL vs 800-1000 under testo TRT), not officially approved, limited long-term data. For users wanting to preserve fertility, interesting option under clinical follow-up.
How long to take enclomiphene in PCT?: 4 weeks standard, extendable to 6-8 weeks if unsatisfactory T total panel at W4 post-PCT. Short half-life (~10 h) allows rapid stop at end of protocol without prolonged accumulation (unlike clomid mixture which can remain active via zuclomiphene for 2-3 weeks after last intake). T total, LH, FSH panel at W4 and W8 post-PCT to confirm recovery.
What side effects under pure enclomiphene?: Theoretically rarer than with clomid mixture. The Androxal program (Repros Therapeutics, never FDA approved) reported a tolerable profile with occasional headaches, hot flashes, and mild nausea. No concerning signal on visual disturbances (attributed to zuclomiphene in clomid). No marked mood effect. Practical profile in bodybuilder PCT limited by lack of direct comparative data. Standard clinical monitoring remains essential.
Enclomiphene to boost testosterone naturally?: This is the use promoted by some alternative TRT clinics. In secondary hypogonadic man (functional but underactive HPG axis), enclomiphene 12.5-25 mg/d can elevate T total by 200-300 ng/dL in a few weeks. Testicle maintenance, fertility preserved, no injection. Drawbacks: plateau effect reached at 6-8 weeks, T total rarely > 800 ng/dL even at high dose. For primary hypogonadism (dysfunctional testicles), ineffective. Primary vs secondary hypogonadism differential diagnosis essential.